Literature DB >> 8790834

Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type.

C Bertoni-Freddari1, P Fattoretti, T Casoli, U Caselli, W Meier-Ruge.   

Abstract

OBJECTIVE: To search for a deterioration threshold of synaptic ultrastructure in physiologic aging and senile dementia of Alzheimer's type (SDAT). STUDY
DESIGN: The numerical density (Nu), average area (S) and surface density (Su) of the synaptic contact zones were investigated in the hippocampus and cerebellum from adults, elderly and SDAT patients by means of computer-assisted morphometry.
RESULTS: The Nu and surface Su densities of the synapses decreased while the size of S enlarged in elderly and SDAT patients vs. the adults. By plotting Nu vs. S, the adult group showed a very high percentage of small junctions. In contrast, elderly and dementia patients demonstrated two overlapping populations of enlarged contacts. In SDAT the synapse-to-neuron ratio was decreased by 48% in the hippocampus and by 56% in the cerebellum.
CONCLUSION: Our findings support the concept that the degeneration of synaptic contacts per se should be considered a crucial step in the progression of senile dementia, but the identification of a discrete deterioration threshold of synaptic morphology between aging and SDAT is not feasible at present.

Entities:  

Mesh:

Year:  1996        PMID: 8790834

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  20 in total

1.  Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

Authors:  Erik Portelius; Henrik Zetterberg; Tobias Skillbäck; Ulrika Törnqvist; Ulf Andreasson; John Q Trojanowski; Michael W Weiner; Leslie M Shaw; Niklas Mattsson; Kaj Blennow
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

2.  Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia.

Authors:  Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin
Journal:  Neurology       Date:  2018-06-29       Impact factor: 9.910

3.  Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease.

Authors:  Maria Manczak; Ramesh Kandimalla; Xiangling Yin; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2018-04-15       Impact factor: 6.150

4.  Presenilin conditional double knockout mice exhibit decreases in drebrin a at hippocampal CA1 synapses.

Authors:  David Lee; Chiye Aoki
Journal:  Synapse       Date:  2012-07-20       Impact factor: 2.562

Review 5.  ADF/Cofilin-actin rods in neurodegenerative diseases.

Authors:  J R Bamburg; B W Bernstein; R C Davis; K C Flynn; C Goldsbury; J R Jensen; M T Maloney; I T Marsden; L S Minamide; C W Pak; A E Shaw; I Whiteman; O Wiggan
Journal:  Curr Alzheimer Res       Date:  2010-05       Impact factor: 3.498

6.  Dietary restriction modulates synaptic structural dynamics in the aging hippocampus.

Authors:  C Bertoni-Freddari; P Fattoretti; U Caselli; T Casoli; G Di Stefano; S Algeri
Journal:  Age (Omaha)       Date:  1999-07

7.  RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.

Authors:  Maria Manczak; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2013-09-21

8.  Compensating for synaptic loss in Alzheimer's disease.

Authors:  Kamal Abuhassan; Damien Coyle; Ammar Belatreche; Liam Maguire
Journal:  J Comput Neurosci       Date:  2013-06-02       Impact factor: 1.621

Review 9.  Molecular mechanisms of the conjugated alpha,beta-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases.

Authors:  Richard M LoPachin; David S Barber; Terrence Gavin
Journal:  Toxicol Sci       Date:  2007-12-13       Impact factor: 4.849

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.